Revolutionary Step: PHASE Scientific Secures $34M for Urine-Based Diagnostics
The medical world is abuzz with excitement as PHASE Scientific, a trailblazer in biotechnology, announces an outstanding $34 million Series A funding round. This influx, the largest of its kind in Asia’s diagnostic sector since 2019, surfaces as a robust endorsement of the proprietary PHASIFY urine-based diagnostics by investors.
Pioneering a New Era in Disease Detection
At the heart of this advancement is PHASIFY’s urine concentration technology, a state-of-the-art method that captures over ten times more biomarkers compared to industry norms. Unlike invasive traditional techniques, PHASIFY offers a transformative, at-home urine collection process. Enabling convenient health management, it marks a significant step forward in preventive and proactive healthcare.
Expansive Test Portfolio and Market Traction
PHASE Scientific’s innovative test offerings span a vast array of health categories. From oncology and women’s health to infectious diseases, the company shows strong market traction. Having distributed over 100 million tests globally, their urine-based HPV test stands out as a world’s first—a groundbreaking innovation that garners significant clinical acclaim.
Strategic Growth and Global Presence
With a strategic base set in Hong Kong, cross-border ties in Southern California, and China’s Greater Bay Area, PHASE Scientific is at the forefront of global healthcare innovation. This geographic trio provides a powerhouse of research, development, and commercialization benefits.
Visionaries Behind the Movement
Dr. Ricky Chiu, the catalyst behind PHASE Scientific, shares, “This landmark funding validates our transformative technology, poised to empower millions through earlier intervention.” Meanwhile, Value Partners Group’s Dr. Chuen Yan Leung praises the company’s paradigm-shifting technology for aligning with their strategy of supporting sector leaders with unparalleled precision and impact.
With the securement of this notable funding, PHASE Scientific is set to accelerate research and development, propelling its mission to pioneer comprehensive, next-generation urine-based diagnostics on a global scale.
According to Pulse 2.0, this funding not only propels PHASE Scientific forward but also highlights the growing importance and viability of non-invasive diagnostic solutions in today’s healthcare landscape.
